本文選題：白介素8 + 白介素10��； 參考：《青島大學(xué)》2017年碩士論文

【摘要】：目的1.探討卵巢癌組織中IL-8基因的表達(dá)及其與卵巢癌臨床病理特征之間的關(guān)系。2.探討卵巢癌組織中IL-10基因的表達(dá)及其與卵巢癌臨床病理特征之間的關(guān)系。3.分析卵巢癌中IL-8和IL-10基因表達(dá)的相關(guān)性以及臨床意義。方法1.分別選用免疫組織化學(xué)染色的方式從蛋白水平及逆轉(zhuǎn)錄-聚合酶鏈反應(yīng)(RT-PCR)的方式從m RNA水平測(cè)驗(yàn)了實(shí)驗(yàn)組(60例卵巢癌組織)和對(duì)照組(30例良性卵巢腫瘤組織、8例正常卵巢組織)內(nèi)IL-8與IL-10表達(dá)的不同。2.使用SPSS17.0軟件對(duì)實(shí)驗(yàn)進(jìn)行統(tǒng)計(jì)分析。-x±s被用來表示計(jì)量資料,t檢驗(yàn)被用來對(duì)兩組進(jìn)行比較,Spearman相關(guān)系數(shù)被用來對(duì)相關(guān)性進(jìn)行分析。Kaplan-Meier法被用來繪制生存曲線,Log-rank檢驗(yàn)被用來比較生存率,多因素Cox比例風(fēng)險(xiǎn)回歸模型被用來分析獨(dú)立危險(xiǎn)因素,P0.05表示差異有明顯的統(tǒng)計(jì)學(xué)的意義。結(jié)果1.IL-8基因在卵巢腫瘤組織中的表達(dá):免疫組化結(jié)果可知實(shí)驗(yàn)組IL-8蛋白呈現(xiàn)高表達(dá),IL-8陽性率為65%(39/60)(P0.05),而對(duì)照組未檢測(cè)到表達(dá);RT-PCR結(jié)果顯示實(shí)驗(yàn)組中IL-8 m RNA的陽性表達(dá)率(0.519士0.077)高于對(duì)照組中IL-8基因的表達(dá)率(0.319士0.077,0.141士0.023)(P0.05)。IL-8蛋白和m RNA水平的表達(dá)與卵巢癌臨床分期、組織分化程度及是否淋巴結(jié)轉(zhuǎn)移有關(guān),IL-8蛋白和m RNA在III-IV期的陽性表達(dá)率分別為(78.05%,0.636±0.082)遠(yuǎn)遠(yuǎn)高于I-II期(36.84%,0.501±0.134)(P0.05),中、低分化組(77.27%,0.569±0.119)遠(yuǎn)遠(yuǎn)高于高分化組(31.25%,0.453±0.139)(P0.05),有淋巴結(jié)轉(zhuǎn)移者(76.92%,0.581±0.115)遠(yuǎn)遠(yuǎn)高于無淋巴結(jié)轉(zhuǎn)移者(42.86%,0.469±0.142)(P0.05),兩者的表達(dá)水平與卵巢癌的病理類型無關(guān)(P0.05);IL-8陰性組(2.86年)生存時(shí)間明顯長于陽性組(2.24年)(P0.01)。2.IL-10基因在卵巢腫瘤組織中的表達(dá):免疫組化結(jié)果可知實(shí)驗(yàn)組IL-10蛋白呈現(xiàn)高表達(dá),IL-10陽性率為63.33%(38/60)(P0.05);RT-PCR結(jié)果顯示實(shí)驗(yàn)組中IL-10基因的陽性表達(dá)率(0.592士0.160)高于對(duì)照組中IL-10基因表達(dá)率(0.391士0.170,0.194土0.042)(P0.05);IL-10蛋白和m RNA水平的表達(dá)與卵巢癌臨床分期、組織分化程度及是否淋巴結(jié)轉(zhuǎn)移有關(guān),IL-10蛋白和m RNA在III-IV期的陽性表達(dá)率分別為(78.05%,0.649±0.117)遠(yuǎn)遠(yuǎn)高于I-II期(31.58%,0.529±0.159)(P0.05),中、低分化組(72.73%,0.614±0.145)遠(yuǎn)遠(yuǎn)高于高分化組(37.50%,0.476±0.163)(P0.05),有淋巴結(jié)轉(zhuǎn)移者(79.49%,0.620±0.142)遠(yuǎn)遠(yuǎn)高于無淋巴結(jié)轉(zhuǎn)移者(33.33%,0.474±0.165)(P0.05),兩者的表達(dá)水平與卵巢癌的病理類型無關(guān)(P0.05);IL-10陰性組(3.14年)生存時(shí)間明顯長于陽性組(2.33年)(P0.01)。3.卵巢癌組織中IL-8和IL-10的表達(dá)具有正相關(guān)性(r=0.461,P0.05)。結(jié)論IL-8與IL-10在卵巢癌組織內(nèi)基因表達(dá)率高,與卵巢癌臨床病理特征有一定相關(guān)性,兩者之間統(tǒng)計(jì)學(xué)分析呈正相關(guān)。其可能作為卵巢癌的分子生物學(xué)標(biāo)志,成為卵巢癌治療的新靶點(diǎn)。
[Abstract]:Objective 1. To investigate the expression of IL-8 gene and its relationship with clinicopathological features of ovarian cancer. To investigate the expression of IL-10 gene and its relationship with clinicopathological features of ovarian cancer. To analyze the correlation and clinical significance of IL-8 and IL-10 gene expression in ovarian cancer. Method 1. Immunohistochemical staining and reverse transcription-polymerase chain reaction RT-PCR were used to test 60 ovarian cancer tissues in the experimental group and 30 benign ovarian tumor tissues in the control group. The difference between IL-8 and IL-10 expression in normal ovarian tissue. The statistical analysis of the experiment using SPSS17.0 software .-x 鹵s was used to indicate that the t test was used to compare the two groups. Kaplan-Meier method was used to analyze the correlation. Kaplan-Meier method was used to draw the survival curve. Log-rank test was used to compare the survival rate. Multivariate Cox proportional risk regression model was used to analyze independent risk factors. Results the expression of 1.IL-8 gene in ovarian neoplasms: the results of immunohistochemistry showed that the positive rate of IL-8 protein in the experimental group was 65 / 39 / 60 / 60 (P0.05A), while that of the control group was not detected by RT-PCR. The results of RT-PCR showed that the positive rate of IL-8 m RNA in the experimental group was higher than that in the control group. The expression rate of IL-8 gene was 0.319 + 0.077 + 0.141 + 0.023)(P0.05).IL-8 protein and m RNA and the clinical stage of ovarian cancer was significantly higher than that in control group (0.519 鹵0.077). The positive expression rates of IL-8 protein and m RNA in the III-IV phase were significantly higher than those in the I-II stage (0.501 鹵0.134), respectively, and the positive rates of IL-8 protein and m RNA were 0.636 鹵0.082 and 0.501 鹵0.134 respectively in the tissue differentiation and lymph node metastasis. The expression level in poorly differentiated group was much higher than that in well-differentiated group (0.453 鹵0.139) P 0.05, and in lymph node metastasis group (76.92 鹵0.115) was much higher than that in non-lymph node metastasis group (0.469 鹵0.142P 0.0519). There was no correlation between the expression level and pathological type of ovarian cancer. The survival time of P0.05 + IL-8 negative group (2.86 years) was significantly longer than that of positive group (2.86 years). Expression of IL-10 gene in ovarian tumor tissues in 2.24 years: the results of immunohistochemistry showed that the positive rate of IL-10 protein in experimental group was 63.33% and the positive rate of IL-10 gene in experimental group was 63.33%. The positive rate of IL-10 gene in experimental group was 0.592 鹵0.160), which was higher than that in control group. The expression of IL-10 protein and m RNA were correlated with the clinical stage of ovarian cancer. The positive expression rates of IL-10 protein and m RNA in the III-IV phase were significantly higher than those in the I-II stage (0. 529 鹵0. 159) and 0. 649 鹵0. 117 respectively. The expression of IL-10 in poorly differentiated group was significantly higher than that in well-differentiated group (0.476 鹵0.163) and lymph node metastasis (79.490.20 鹵0.142). It was significantly higher in poorly differentiated group than in non-lymph node metastasis group (0.474 鹵0.165P0.05). The expression level was not related to the pathological type of ovarian cancer. The survival time of the negative group (3.14) was significantly longer than that of the positive group (2.33 years, P 0.01T. There was a positive correlation between the expression of IL-8 and IL-10 in ovarian cancer tissues. Conclusion the gene expression rate of IL-8 and IL-10 in ovarian cancer is high, and there is a certain correlation with clinicopathological characteristics of ovarian cancer, and there is a positive correlation between them. It may be a molecular marker of ovarian cancer and a new target for ovarian cancer therapy.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張林風(fēng);孫文妹;李文娟;;先期化療聯(lián)合腫瘤細(xì)胞減滅術(shù)后腹腔熱灌注化療治療晚期卵巢癌的臨床療效分析[J];實(shí)用癌癥雜志;2016年09期

2 羅繼紅;;紫杉醇聯(lián)合順鉑不同給藥途徑治療晚期卵巢癌的療效觀察[J];醫(yī)學(xué)理論與實(shí)踐;2016年16期

3 廖曉燕;;影響上皮性卵巢癌術(shù)后復(fù)發(fā)的相關(guān)危險(xiǎn)因素[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年14期

4 張爽爽;夏慶民;鄭榮壽;陳萬青;;中國2010年卵巢癌發(fā)病與死亡分析[J];中國腫瘤;2016年03期

5 雷婧;郭瑞霞;郭濤;吳忱莼;喬玉環(huán);;SDF-1和PI3K/Akt通路對(duì)卵巢癌CAOV3細(xì)胞增殖和侵襲能力的影響研究[J];中國婦幼保健;2015年15期

6 孫琮;童曉文;;新輔助化療對(duì)晚期卵巢癌的療效評(píng)價(jià)[J];醫(yī)學(xué)綜述;2015年05期

7 白萍;舒桐;孫慧;;靶向治療對(duì)復(fù)發(fā)性耐藥性卵巢癌的治療價(jià)值[J];中國實(shí)用婦科與產(chǎn)科雜志;2015年03期

8 譚文福;張帆;;腹腔灌注聯(lián)合靜脈化療治療晚期卵巢癌療效觀察[J];武漢大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2015年01期

9 柏艷芳;黃中英;李鳳姣;周怡;;腹腔熱灌注化療在卵巢癌患者細(xì)胞減滅術(shù)中的應(yīng)用配合[J];護(hù)理學(xué)報(bào);2014年08期

10 徐兵;周穎;胡衛(wèi)平;;上皮性卵巢癌起源學(xué)說的研究進(jìn)展[J];國際婦產(chǎn)科學(xué)雜志;2014年02期

相關(guān)碩士學(xué)位論文 前1條

1 曾瀝瓊;循環(huán)腫瘤細(xì)胞對(duì)卵巢癌預(yù)后預(yù)測(cè)價(jià)值的meta分析[D];重慶醫(yī)科大學(xué);2014年

，

本文編號(hào)：1897021